Regulatory Affairs Outsourcing Market (By Service: Legal Representation, Regulatory Consulting, Product Registration & Clinical Trial Application, Regulatory Writing & Publication, Others; By Category: Biologics, Drugs, Medical Devices; By End User: Medical Device Company, Biotechnology Company, and Pharmaceutical Company; By Indication: Neurology, Oncology, Immunology, Cardiology, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
The global regulatory affairs outsourcing market was estimated at USD 6.7 billion in 2022 and is expected to reach USD 15.5 billion by 2032, poised to grow at a compound annual growth rate (CAGR) of 8.8% during the forecast period from 2023 to 2032.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The high costs associated with the operations of regulatory affairs are significant factors that drive the demand for regulatory affairs outsourcing. Complying with the various regulatory norms of the local regulatory authorities in the major markets like North America, Asia Pacific, and Europe is a challenging task for the companies especially the multinationals. There are various companies like medical device manufacturers, pharmaceutical developers, and biotechnology companies that have increased demand for outsourcing regulatory affairs. The outsourcing of regulatory affairs has become more important owing to the expansion activities and development of new devices and drugs by the numerous companies operating in the healthcare sector. The regular efforts for the development of new drugs and equipment result in an increased number of approvals regarding the preclinical and clinical trials. Therefore, in order to focus on the core activities and efficiently handle the regulatory affairs at low cost, the companies are increasingly adopting for the regulator affairs service providers, thereby boosting the demands for the services across the globe.
There are various activities such as new product registration, preclinical trials application, regulatory compliances, and activities related to post market authorization, which is a challenging task. The need to comply with the regulations and continuous need for tracking the updates in the regulations is driving the adoption of the regulatory affairs outsourcing services. Further, the development of the software that provides regulatory solutions and keeps the records of various activities and departments such as clinical trials, product registration, change management, and performance tracking, is expected to fuel the growth of the global regulatory affairs outsourcing market.
| Report Highlights | Details |
| Market Size in 2023 | USD 7.26 Billion |
| Market Size by 2032 | USD 15.5 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 8.8% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Service, Category, End User, Indication, Stage |
| Regional Scope |
|
| Companies Mentioned | Medpace, ICON Plc, WuXiAppTec, Inc., Covance, Genpact Ltd., Pharmaceutical Product Development LLC., Freyr, PRA Health Sciences, Criterium, Inc., Accell Clinical Research, LLC. |
Based on service, the regulatory writing & publication segment accounted for over 35% of the market share in 2022 and is projected to sustain its dominance during the forecast period. Regulatory writing and publishing is considered to be an integral part of the research. A wide variety of documents are produced throughout the clinical trial phases. Further, the regulatory writers are considered to be an essential communicator between the drug developers and the approving regulatory authorities such as FDA and EMA. The regulatory writers also play an important role in the advertising of any new drug or medical device. Hence, the significance of the regulatory writing and publication activities has made this the leading segment across the globe.
The legal representation segment is expected to be the most opportunistic segment owing to the rising penetration and expansion activities of the numerous biopharmaceutical and medical device companies across various nations of the globe. For instance, a biopharmaceutical company, based in the US, may require legal representation in order to get the market authorization and sell its products in India. Globalization is the major driver of this segment.
Based on category, the medical devices segment accounted for more than 35% of the market share in 2022 and is expected to sustain its dominance during the forecast period. The rising demand for innovative medical devices across the hospitals and clinics has led the medical devices companies to focus on their core activities and outsource the regulatory affairs activities. The medical devices companies are constantly engaged in the development of the latest and innovative diagnostic and medical devices and hence are increasingly adopting the regulatory affairs services to increase its operational efficiencies.
Biologics are expected to be the fastest-growing segment during the forecast period. This is attributed to the rapid growth of the biologics industry across the globe, owing to its rising popularity of various life-saving drugs. The increasing investments on the research & development of the various new biologic drugs require frequent preclinical and clinical approvals and regulatory writing services in order to get approval and market authorization across various countries.
Based on end user, the pharmaceutical company segment accounted for over 37% of the market share in 2022 and is expected to sustain its dominance during the forecast period. This can be attributed to the rapid growth and popularity of biopharmaceuticals and the rising adoption of biosimilar, personalized drugs, and orphan drugs among the population. The rapidly expanding biopharmaceutical industry is expected to further drive the growth of this segment in the upcoming future.
The medical device company is expected to register the highest CAGR during the forecast period. The rising investments in the growth of the medical devices companies are fueling the growth of this segment. The rising research and development activities of the medical device companies is expected to drive the growth of this segment owing to the increasing need for regulatory writing and publication activities, in the forthcoming years.
Based on indication, the oncology segment accounted for more than 32% of the market share in 2022 and is predicted to sustain its dominance during the forecast period. The development of the various therapeutics and drugs for the treatment of cancer in the past years has had significantly impacted the growth of this segment. Moreover, the surging popularity of personalized medicines is expected to drive the demand for regulatory affairs outsourcing in the upcoming years.
On the other hand, neurology is estimated to be the fastest-growing segment. The rising prevalence of neurological disorders among the population has attracted increased investments in the development of new neurological medicines and medical equipment, which will increase the regulatory affairs related activities such as product registration, regulatory writing, and legal representation. This factor may propel the growth of this segment during the forecast period.
Based on stage, the clinical segment accounted for more than 45% of the market share in 2022 and is predicted to sustain its dominance during the forecast period. This can be attributed to the increasing number of clinical trials. According to ClinicalTrials.gov, around 326,000 clinical trials were registered in 2019 in the US which increased to more than 347,000 clinical trials in 2020. Therefore, the rising number of clinical trials is expected to retain the dominance of this segment throughout the forecast period.
On the other hand, the preclinical segment is estimated to be the most opportunistic segment during the forecast period. The rising activities relating to the new product developments by the pharmaceutical and medical device companies are the primary factors that are expected to drive the growth of this segment in the foreseeable future.
Based on region, Asia Pacific garnered around 37% of the market share in 2022. The growing presence of numerous pharmaceutical and medical device companies in the region owing to the easy and cheap availability of raw materials for drugs and electronic medical devices has boosted the growth of this region.
The rising investments by the government to attract FDIs are further expected to drive the growth of the market in the Asia Pacific. The countries like China, India, Indonesia, and South Korea are expected to attract investments from numerous healthcare companies that is anticipated to drive the growth of the regulatory affairs outsourcing market in the region.
Key Companies & Market Share Insights
The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.
In 2019, Accell and Syntax collaborated to expand their client reach in Europe. The various developmental strategies like collaborations, mergers, acquisitions and partnerships foster market growth and offers lucrative growth opportunities to the market players.
Market Segmentation
By Service
By Category
By End User
By Indication
By Stage
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Regulatory Affairs Outsourcing Market
5.1. COVID-19 Landscape: Regulatory Affairs Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Regulatory Affairs Outsourcing Market, By Service
8.1. Regulatory Affairs Outsourcing Market, by Service, 2023-2032
8.1.1. Legal Representation
8.1.1.1. Market Revenue and Forecast (2021-2032)
8.1.2. Regulatory Consulting
8.1.2.1. Market Revenue and Forecast (2021-2032)
8.1.3. Product Registration & Clinical Trial Application
8.1.3.1. Market Revenue and Forecast (2021-2032)
8.1.4. Regulatory Writing & Publication
8.1.4.1. Market Revenue and Forecast (2021-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2032)
Chapter 9. Global Regulatory Affairs Outsourcing Market, By Category
9.1. Regulatory Affairs Outsourcing Market, by Category, 2023-2032
9.1.1. Biologics
9.1.1.1. Market Revenue and Forecast (2021-2032)
9.1.2. Drugs
9.1.2.1. Market Revenue and Forecast (2021-2032)
9.1.3. Medical Devices
9.1.3.1. Market Revenue and Forecast (2021-2032)
Chapter 10. Global Regulatory Affairs Outsourcing Market, By End User
10.1. Regulatory Affairs Outsourcing Market, by End User, 2023-2032
10.1.1. Medical Device Company
10.1.1.1. Market Revenue and Forecast (2021-2032)
10.1.2. Biotechnology Company
10.1.2.1. Market Revenue and Forecast (2021-2032)
10.1.3. Pharmaceutical Company
10.1.3.1. Market Revenue and Forecast (2021-2032)
Chapter 11. Global Regulatory Affairs Outsourcing Market, By Indication
11.1. Regulatory Affairs Outsourcing Market, by Indication, 2023-2032
11.1.1. Neurology
11.1.1.1. Market Revenue and Forecast (2021-2032)
11.1.2. Oncology
11.1.2.1. Market Revenue and Forecast (2021-2032)
11.1.3. Immunology
11.1.3.1. Market Revenue and Forecast (2021-2032)
11.1.4. Cardiology
11.1.4.1. Market Revenue and Forecast (2021-2032)
11.1.5. Others
11.1.5.1. Market Revenue and Forecast (2021-2032)
Chapter 12. Global Regulatory Affairs Outsourcing Market, By Stage
12.1. Regulatory Affairs Outsourcing Market, by Stage, 2023-2032
12.1.1. Clinical
12.1.1.1. Market Revenue and Forecast (2021-2032)
12.1.2. Preclinical
12.1.2.1. Market Revenue and Forecast (2021-2032)
12.1.3. Post Market Authorization
12.1.3.1.Market Revenue and Forecast (2021-2032)
Chapter 13. Global Regulatory Affairs Outsourcing Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Service (2021-2032)
13.1.2. Market Revenue and Forecast, by Category (2021-2032)
13.1.3. Market Revenue and Forecast, by End User (2021-2032)
13.1.4. Market Revenue and Forecast, by Indication (2021-2032)
13.1.5. Market Revenue and Forecast, by Stage (2021-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Service (2021-2032)
13.1.6.2. Market Revenue and Forecast, by Category (2021-2032)
13.1.6.3. Market Revenue and Forecast, by End User (2021-2032)
13.1.6.4. Market Revenue and Forecast, by Indication (2021-2032)
13.1.7. Market Revenue and Forecast, by Stage (2021-2032)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Service (2021-2032)
13.1.8.2. Market Revenue and Forecast, by Category (2021-2032)
13.1.8.3. Market Revenue and Forecast, by End User (2021-2032)
13.1.8.4. Market Revenue and Forecast, by Indication (2021-2032)
13.1.8.5. Market Revenue and Forecast, by Stage (2021-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Service (2021-2032)
13.2.2. Market Revenue and Forecast, by Category (2021-2032)
13.2.3. Market Revenue and Forecast, by End User (2021-2032)
13.2.4. Market Revenue and Forecast, by Indication (2021-2032)
13.2.5. Market Revenue and Forecast, by Stage (2021-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Service (2021-2032)
13.2.6.2. Market Revenue and Forecast, by Category (2021-2032)
13.2.6.3. Market Revenue and Forecast, by End User (2021-2032)
13.2.7. Market Revenue and Forecast, by Indication (2021-2032)
13.2.8. Market Revenue and Forecast, by Stage (2021-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Service (2021-2032)
13.2.9.2. Market Revenue and Forecast, by Category (2021-2032)
13.2.9.3. Market Revenue and Forecast, by End User (2021-2032)
13.2.10. Market Revenue and Forecast, by Indication (2021-2032)
13.2.11. Market Revenue and Forecast, by Stage (2021-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Service (2021-2032)
13.2.12.2. Market Revenue and Forecast, by Category (2021-2032)
13.2.12.3. Market Revenue and Forecast, by End User (2021-2032)
13.2.12.4. Market Revenue and Forecast, by Indication (2021-2032)
13.2.13. Market Revenue and Forecast, by Stage (2021-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Service (2021-2032)
13.2.14.2. Market Revenue and Forecast, by Category (2021-2032)
13.2.14.3. Market Revenue and Forecast, by End User (2021-2032)
13.2.14.4. Market Revenue and Forecast, by Indication (2021-2032)
13.2.15. Market Revenue and Forecast, by Stage (2021-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Service (2021-2032)
13.3.2. Market Revenue and Forecast, by Category (2021-2032)
13.3.3. Market Revenue and Forecast, by End User (2021-2032)
13.3.4. Market Revenue and Forecast, by Indication (2021-2032)
13.3.5. Market Revenue and Forecast, by Stage (2021-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Service (2021-2032)
13.3.6.2. Market Revenue and Forecast, by Category (2021-2032)
13.3.6.3. Market Revenue and Forecast, by End User (2021-2032)
13.3.6.4. Market Revenue and Forecast, by Indication (2021-2032)
13.3.7. Market Revenue and Forecast, by Stage (2021-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Service (2021-2032)
13.3.8.2. Market Revenue and Forecast, by Category (2021-2032)
13.3.8.3. Market Revenue and Forecast, by End User (2021-2032)
13.3.8.4. Market Revenue and Forecast, by Indication (2021-2032)
13.3.9. Market Revenue and Forecast, by Stage (2021-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Service (2021-2032)
13.3.10.2. Market Revenue and Forecast, by Category (2021-2032)
13.3.10.3. Market Revenue and Forecast, by End User (2021-2032)
13.3.10.4. Market Revenue and Forecast, by Indication (2021-2032)
13.3.10.5. Market Revenue and Forecast, by Stage (2021-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Service (2021-2032)
13.3.11.2. Market Revenue and Forecast, by Category (2021-2032)
13.3.11.3. Market Revenue and Forecast, by End User (2021-2032)
13.3.11.4. Market Revenue and Forecast, by Indication (2021-2032)
13.3.11.5. Market Revenue and Forecast, by Stage (2021-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Service (2021-2032)
13.4.2. Market Revenue and Forecast, by Category (2021-2032)
13.4.3. Market Revenue and Forecast, by End User (2021-2032)
13.4.4. Market Revenue and Forecast, by Indication (2021-2032)
13.4.5. Market Revenue and Forecast, by Stage (2021-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Service (2021-2032)
13.4.6.2. Market Revenue and Forecast, by Category (2021-2032)
13.4.6.3. Market Revenue and Forecast, by End User (2021-2032)
13.4.6.4. Market Revenue and Forecast, by Indication (2021-2032)
13.4.7. Market Revenue and Forecast, by Stage (2021-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Service (2021-2032)
13.4.8.2. Market Revenue and Forecast, by Category (2021-2032)
13.4.8.3. Market Revenue and Forecast, by End User (2021-2032)
13.4.8.4. Market Revenue and Forecast, by Indication (2021-2032)
13.4.9. Market Revenue and Forecast, by Stage (2021-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Service (2021-2032)
13.4.10.2. Market Revenue and Forecast, by Category (2021-2032)
13.4.10.3. Market Revenue and Forecast, by End User (2021-2032)
13.4.10.4. Market Revenue and Forecast, by Indication (2021-2032)
13.4.10.5. Market Revenue and Forecast, by Stage (2021-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Service (2021-2032)
13.4.11.2. Market Revenue and Forecast, by Category (2021-2032)
13.4.11.3. Market Revenue and Forecast, by End User (2021-2032)
13.4.11.4. Market Revenue and Forecast, by Indication (2021-2032)
13.4.11.5. Market Revenue and Forecast, by Stage (2021-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Service (2021-2032)
13.5.2. Market Revenue and Forecast, by Category (2021-2032)
13.5.3. Market Revenue and Forecast, by End User (2021-2032)
13.5.4. Market Revenue and Forecast, by Indication (2021-2032)
13.5.5. Market Revenue and Forecast, by Stage (2021-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Service (2021-2032)
13.5.6.2. Market Revenue and Forecast, by Category (2021-2032)
13.5.6.3. Market Revenue and Forecast, by End User (2021-2032)
13.5.6.4. Market Revenue and Forecast, by Indication (2021-2032)
13.5.7. Market Revenue and Forecast, by Stage (2021-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Service (2021-2032)
13.5.8.2. Market Revenue and Forecast, by Category (2021-2032)
13.5.8.3. Market Revenue and Forecast, by End User (2021-2032)
13.5.8.4. Market Revenue and Forecast, by Indication (2021-2032)
13.5.8.5. Market Revenue and Forecast, by Stage (2021-2032)
Chapter 14. Company Profiles
14.1. Medpace
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. ICON Plc
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. WuXiAppTec, Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Covance
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Genpact Ltd.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Pharmaceutical Product Development LLC.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Freyr
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. PRA Health Sciences
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Criterium, Inc.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Accell Clinical Research, LLC.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
